Cargando…

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer

The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cieślikowski, Wojciech A., Milecki, Piotr, Świerczewska, Monika, Ida, Agnieszka, Kasperczak, Michał, Jankowiak, Agnieszka, Nowicki, Michał, Pantel, Klaus, Alix-Panabières, Catherine, Zabel, Maciej, Antczak, Andrzej, Budna-Tukan, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144132/
https://www.ncbi.nlm.nih.gov/pubmed/37108995
http://dx.doi.org/10.3390/jpm13040608
_version_ 1785034029106462720
author Cieślikowski, Wojciech A.
Milecki, Piotr
Świerczewska, Monika
Ida, Agnieszka
Kasperczak, Michał
Jankowiak, Agnieszka
Nowicki, Michał
Pantel, Klaus
Alix-Panabières, Catherine
Zabel, Maciej
Antczak, Andrzej
Budna-Tukan, Joanna
author_facet Cieślikowski, Wojciech A.
Milecki, Piotr
Świerczewska, Monika
Ida, Agnieszka
Kasperczak, Michał
Jankowiak, Agnieszka
Nowicki, Michał
Pantel, Klaus
Alix-Panabières, Catherine
Zabel, Maciej
Antczak, Andrzej
Budna-Tukan, Joanna
author_sort Cieślikowski, Wojciech A.
collection PubMed
description The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch(®) system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56–74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch(®) system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter.
format Online
Article
Text
id pubmed-10144132
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101441322023-04-29 Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer Cieślikowski, Wojciech A. Milecki, Piotr Świerczewska, Monika Ida, Agnieszka Kasperczak, Michał Jankowiak, Agnieszka Nowicki, Michał Pantel, Klaus Alix-Panabières, Catherine Zabel, Maciej Antczak, Andrzej Budna-Tukan, Joanna J Pers Med Article The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch(®) system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56–74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch(®) system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter. MDPI 2023-03-30 /pmc/articles/PMC10144132/ /pubmed/37108995 http://dx.doi.org/10.3390/jpm13040608 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cieślikowski, Wojciech A.
Milecki, Piotr
Świerczewska, Monika
Ida, Agnieszka
Kasperczak, Michał
Jankowiak, Agnieszka
Nowicki, Michał
Pantel, Klaus
Alix-Panabières, Catherine
Zabel, Maciej
Antczak, Andrzej
Budna-Tukan, Joanna
Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
title Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
title_full Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
title_fullStr Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
title_full_unstemmed Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
title_short Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
title_sort baseline ctc count as a predictor of long-term outcomes in high-risk prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144132/
https://www.ncbi.nlm.nih.gov/pubmed/37108995
http://dx.doi.org/10.3390/jpm13040608
work_keys_str_mv AT cieslikowskiwojciecha baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT mileckipiotr baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT swierczewskamonika baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT idaagnieszka baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT kasperczakmichał baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT jankowiakagnieszka baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT nowickimichał baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT pantelklaus baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT alixpanabierescatherine baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT zabelmaciej baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT antczakandrzej baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer
AT budnatukanjoanna baselinectccountasapredictoroflongtermoutcomesinhighriskprostatecancer